---
document_datetime: 2025-12-02 05:15:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/adtralza.html
document_name: adtralza.html
version: success
processing_time: 0.1132223
conversion_datetime: 2025-12-23 21:21:12.221131
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Adtralza

[RSS](/en/individual-human-medicine.xml/67446)

##### Authorised

This medicine is authorised for use in the European Union

tralokinumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Adtralza](#news-on)
- [More information on Adtralza](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Adtralza is a medicine for treating adults and children above 12 years of age with moderate to severe atopic dermatitis (also known as eczema, when the skin is itchy, red and dry). It is used in patients for whom treatment applied directly to the skin cannot be used or is not sufficient.

Adtralza contains the active substance tralokinumab.

Expand section

Collapse section

## How is Adtralza used?

Adtralza is available as a solution for injection under the skin. The first dose is four injections of 150 mg, each into a different location. This is followed by two injections of 150 mg every two weeks. The medicine can only be obtained with a prescription. For more information about using Adtralza, see the package leaflet or contact your doctor or pharmacist.

## How does Adtralza work?

Patients with atopic dermatitis produce high levels of proteins called interleukin 13 (IL-13), which can cause inflammation of the skin leading to the symptoms of this disease such as redness, swelling and itching. The active substance in Adtralza, tralokinumab, is a type of protein (monoclonal antibody) designed  to neutralise IL-13. By neutralising IL-13, tralokinumab prevents IL-13 from working and thereby reduces the inflammation and patient's symptoms.

## What benefits of Adtralza have been shown in studies?

Adtralza was more effective than a placebo (dummy treatment) at reducing the extent and severity of atopic dermatitis after 16 weeks of treatment in three main studies in adult patients with moderate to severe disease that had not responded well enough to treatment applied to the skin. The main measures of effectiveness were having clear or almost clear skin, and a reduction in symptom score of at least 75%.

In the first study, which involved 802 patients, around 16% of patients who received Adtralza had clear skin or almost clear skin compared with 7% of those who received placebo. Symptoms were satisfactorily reduced in 25% of patients who received Adtralza, compared with about 13% of those who received placebo.

In the second study, involving 794 patients, treatment with Adtralza led to clear or almost clear skin in about 22% of patients, compared with around 11% of patients who used a placebo. Symptoms were satisfactorily reduced in 33% of patients receiving Adtralza versus about 11% of those receiving placebo.

In the third study, 380 patients were given Adtralza or placebo, both in combination with a topical corticosteroid (a medicine for inflammation applied to the skin). Adtralza treatment led to clear or almost clear skin in around 39% of patients versus 26% of those receiving placebo. Symptoms were satisfactorily reduced in 56% of the patients who received Adtralza, compared with about 36% of patients on placebo.

In an additional study involving 301 children aged between 12 and 17 years with atopic dermatitis, treatment with Adtralza 300 mg every two weeks for 16 weeks led to clear or almost clear skin in around 18% of patients, while treatment with 150 mg every other week for 16 weeks led to clear or almost clear skin in around 21% of patients. This compared with around 4% of patients who used a placebo.

## What are the risks associated with Adtralza?

The most common side effects with Adtralza in adults are upper respiratory tract infections (colds and other infections of the nose and throat) which may affect more than 1 in 10 people. Other common side effects include reactions at the injection site and redness and discomfort in the eye (which may affect up to 1 in 10 people). In children, studies showed that the safety profile is similar to that in adults.

For the full list of side effects and restrictions of Adtralza, see the package leaflet.

## Why is Adtralza authorised in the EU?

Four main studies have shown that Adtralza is effective at clearing the skin and reducing symptoms of atopic dermatitis. The side effects are considered manageable. The European Medicines Agency decided that Adtralza's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Adtralza?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Adtralza have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Adtralza are continuously monitored. Side effects reported with Adtralza are carefully evaluated and any necessary action taken to protect patients.

## Other information about Adtralza

Adtralza received a marketing authorisation valid throughout the EU on 17 June 2021.

Adtralza : EPAR - Medicine overview

Reference Number: EMA/249552/2021

English (EN) (111.49 KB - PDF)

**First published:** 22/06/2021

**Last updated:** 25/11/2022

[View](/en/documents/overview/adtralza-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-84)

български (BG) (136.59 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/bg/documents/overview/adtralza-epar-medicine-overview_bg.pdf)

español (ES) (112.1 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/es/documents/overview/adtralza-epar-medicine-overview_es.pdf)

čeština (CS) (134.38 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/cs/documents/overview/adtralza-epar-medicine-overview_cs.pdf)

dansk (DA) (110.43 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/da/documents/overview/adtralza-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.03 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/de/documents/overview/adtralza-epar-medicine-overview_de.pdf)

eesti keel (ET) (99.15 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/et/documents/overview/adtralza-epar-medicine-overview_et.pdf)

ελληνικά (EL) (133.62 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/el/documents/overview/adtralza-epar-medicine-overview_el.pdf)

français (FR) (113.6 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/fr/documents/overview/adtralza-epar-medicine-overview_fr.pdf)

hrvatski (HR) (142.82 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/hr/documents/overview/adtralza-epar-medicine-overview_hr.pdf)

italiano (IT) (119.93 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/it/documents/overview/adtralza-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (151.67 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/lv/documents/overview/adtralza-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (144.41 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/lt/documents/overview/adtralza-epar-medicine-overview_lt.pdf)

magyar (HU) (143.25 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/hu/documents/overview/adtralza-epar-medicine-overview_hu.pdf)

Malti (MT) (160.23 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/mt/documents/overview/adtralza-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.4 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/nl/documents/overview/adtralza-epar-medicine-overview_nl.pdf)

polski (PL) (145.42 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/pl/documents/overview/adtralza-epar-medicine-overview_pl.pdf)

português (PT) (121.69 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/pt/documents/overview/adtralza-epar-medicine-overview_pt.pdf)

română (RO) (142.26 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/ro/documents/overview/adtralza-epar-medicine-overview_ro.pdf)

slovenčina (SK) (142.94 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/sk/documents/overview/adtralza-epar-medicine-overview_sk.pdf)

slovenščina (SL) (170.58 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/sl/documents/overview/adtralza-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.07 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/fi/documents/overview/adtralza-epar-medicine-overview_fi.pdf)

svenska (SV) (120.06 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

25/11/2022

[View](/sv/documents/overview/adtralza-epar-medicine-overview_sv.pdf)

Adtralza : EPAR - Risk management plan

English (EN) (3.03 MB - PDF)

**First published:** 27/10/2025

[View](/en/documents/rmp/adtralza-epar-risk-management-plan_en.pdf)

## Product information

Adtralza : EPAR - Product Information

English (EN) (1.24 MB - PDF)

**First published:** 22/06/2021

**Last updated:** 27/10/2025

[View](/en/documents/product-information/adtralza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-13)

български (BG) (1.27 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/bg/documents/product-information/adtralza-epar-product-information_bg.pdf)

español (ES) (1.23 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/es/documents/product-information/adtralza-epar-product-information_es.pdf)

čeština (CS) (1.34 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/cs/documents/product-information/adtralza-epar-product-information_cs.pdf)

dansk (DA) (1.17 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/da/documents/product-information/adtralza-epar-product-information_da.pdf)

Deutsch (DE) (1.22 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/de/documents/product-information/adtralza-epar-product-information_de.pdf)

eesti keel (ET) (1.27 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/et/documents/product-information/adtralza-epar-product-information_et.pdf)

ελληνικά (EL) (1.27 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/el/documents/product-information/adtralza-epar-product-information_el.pdf)

français (FR) (1.2 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/fr/documents/product-information/adtralza-epar-product-information_fr.pdf)

hrvatski (HR) (1.2 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/hr/documents/product-information/adtralza-epar-product-information_hr.pdf)

íslenska (IS) (1.18 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/is/documents/product-information/adtralza-epar-product-information_is.pdf)

italiano (IT) (1.28 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/it/documents/product-information/adtralza-epar-product-information_it.pdf)

latviešu valoda (LV) (1.24 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/lv/documents/product-information/adtralza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.32 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/lt/documents/product-information/adtralza-epar-product-information_lt.pdf)

magyar (HU) (1.27 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/hu/documents/product-information/adtralza-epar-product-information_hu.pdf)

Malti (MT) (1.32 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/mt/documents/product-information/adtralza-epar-product-information_mt.pdf)

Nederlands (NL) (1.18 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/nl/documents/product-information/adtralza-epar-product-information_nl.pdf)

norsk (NO) (1.18 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/no/documents/product-information/adtralza-epar-product-information_no.pdf)

polski (PL) (1.29 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/pl/documents/product-information/adtralza-epar-product-information_pl.pdf)

português (PT) (1.27 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/pt/documents/product-information/adtralza-epar-product-information_pt.pdf)

română (RO) (1.28 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/ro/documents/product-information/adtralza-epar-product-information_ro.pdf)

slovenčina (SK) (1.33 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/sk/documents/product-information/adtralza-epar-product-information_sk.pdf)

slovenščina (SL) (1.34 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/sl/documents/product-information/adtralza-epar-product-information_sl.pdf)

Suomi (FI) (1.17 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/fi/documents/product-information/adtralza-epar-product-information_fi.pdf)

svenska (SV) (1.18 MB - PDF)

**First published:**

22/06/2021

**Last updated:**

27/10/2025

[View](/sv/documents/product-information/adtralza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000254976 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Adtralza : EPAR - All Authorised presentations

English (EN) (66.95 KB - PDF)

**First published:** 22/06/2021

**Last updated:** 29/11/2023

[View](/en/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-22)

български (BG) (64.13 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/bg/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.89 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/es/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (65.93 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/cs/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.79 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/da/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.16 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/de/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.22 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/et/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.65 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/el/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_el.pdf)

français (FR) (47.56 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/fr/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (88.14 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/hr/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.21 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/is/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.02 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/it/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (67.56 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/lv/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (67.72 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/lt/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (68.81 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/hu/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (69.96 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/mt/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.83 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/nl/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.33 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/no/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_no.pdf)

polski (PL) (69.33 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/pl/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.54 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/pt/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.32 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/ro/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (67.81 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/sk/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.81 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/sl/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.09 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/fi/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.01 KB - PDF)

**First published:**

22/06/2021

**Last updated:**

29/11/2023

[View](/sv/documents/all-authorised-presentations/adtralza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Adtralza Active substance tralokinumab International non-proprietary name (INN) or common name tralokinumab Therapeutic area (MeSH) Dermatitis, Atopic Anatomical therapeutic chemical (ATC) code D11

### Pharmacotherapeutic group

Other dermatological preparations

### Therapeutic indication

Adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/005255

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

LEO Pharma A/S

Industriparken 55

Opinion adopted 22/04/2021 Marketing authorisation issued 17/06/2021 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Adtralza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (131.13 KB - PDF)

**First published:** 19/05/2025

**Last updated:** 27/10/2025

[View](/en/documents/procedural-steps-after/adtralza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Adtralza : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (156.17 KB - PDF)

**First published:** 25/11/2022

**Last updated:** 19/05/2025

[View](/en/documents/procedural-steps-after/adtralza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Adtralza-PAM-0000258539 : EPAR - Assessment report

Reference Number: EMADOC-1700519818-2197482

English (EN) (4.4 MB - PDF)

**First published:** 24/06/2025

[View](/en/documents/variation-report/adtralza-pam-0000258539-epar-assessment-report_en.pdf)

Adtralza-H-C-005255-II-0002 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/742229/2022

English (EN) (5.78 MB - PDF)

**First published:** 25/11/2022

[View](/en/documents/variation-report/adtralza-h-c-005255-ii-0002-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Adtralza (II-0002)

Adopted

Reference Number: EMA/CHMP/742227/2022

English (EN) (118.36 KB - PDF)

**First published:** 16/09/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-adtralza-ii-0002_en.pdf)

## Initial marketing authorisation documents

Adtralza : EPAR - Public assessment report

Adopted

Reference Number: EMA/266138/2021

English (EN) (5.49 MB - PDF)

**First published:** 22/06/2021

[View](/en/documents/assessment-report/adtralza-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Adtralza

Adopted

Reference Number: EMA/CHMP/202204/2021

English (EN) (125.02 KB - PDF)

**First published:** 23/04/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-adtralza_en.pdf)

#### News on Adtralza

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

#### More information on Adtralza

- [EMEA-001900-PIP02-17-M08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001900-pip02-17-m08)
- [Post-authorisation Safety Study of Tralokinumab Use in Pregnancy: An Observational Study Based on Electronic Healthcare Data - post-authorisation study](https://catalogues.ema.europa.eu/study/104924)
- [Spanish Registry of Atopic Dermatitis (BIOBADATOP) - post-authorisation study](https://catalogues.ema.europa.eu/study/31712)
- [Tralokinumab real world clinical use: An observational cohort study of atopic dermatitis patients prescribed tralokinumab (TRACE) - post-authorisation study](https://catalogues.ema.europa.eu/study/45677)

**This page was last updated on** 27/10/2025

## Share this page

[Back to top](#main-content)